Arrowhead Pharmaceuticals (ARWR) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
18 Nov, 2026Platform and portfolio
RNAi platform reaches seven cell types, with clinical studies in five; 23 drug candidates are in clinical study, roughly half partnered and half wholly owned.
REDEMPLO launched for FCS earlier in 2026; an sNDA to expand use to sHTG was filed Nov. 2, with a potential decision in the March-April timeframe after a review of up to six months.
ARO-MAPT showed clinical proof of concept for subcutaneous delivery to the brain and tau knockdown; ARO-DIMER combines PCSK9 and APOC3 knockdown to address LDL and triglycerides.
REDEMPLO evidence and sHTG opportunity
SHASTA-3 and SHASTA-4 showed an 80% triglyceride reduction from baseline, lower pancreatitis rates, and a favorable safety profile without increased liver fat or meaningful ALT increases.
REDEMPLO is dosed quarterly; reported safety findings included no liver-fat increases, hypersensitivity, thrombocytopenia, or ALT increases, with an NNT of three over 12 months to prevent one pancreatitis episode in the specified high-risk group.
Estimated U.S. sHTG population is 3 million-3.5 million with triglycerides above 500 mg/dL; roughly 1 million are considered very high risk, including patients with prior pancreatitis or triglycerides above 880 mg/dL.
Peak annual U.S. sales potential was estimated at $3B-$4B; the $45,000 annual list price reflects a differentiated pancreatitis-risk and safety profile, with broader market penetration dependent on physician education.
SHASTA-5, an event-driven study in high-risk patients, will continue into 2027; longer-term pancreatitis-risk data could support education and marketing, including in Europe.
Commercial launch and positioning
Payer discussions are underway ahead of potential sHTG approval; launch tracking will emphasize prescriptions, prescribing physicians, and covered lives, alongside revenue.
FCS coverage reached roughly 160 million covered lives; prescriptions were running at 50-60 new starts weekly, while payer policy and coverage processes continued to delay conversion to paid shipments.
The commercial team is largely ramped, with a small additional hiring wave expected in January; the launch strategy prioritizes expanding the treated market, with switches potentially growing over time based on quarterly dosing and safety differentiation.
The list price is $45,000 per year, described as a 12.5% premium to TRYNGOLZA; limited discounting was reported in FCS, while sHTG payer response remains to be seen.
Latest events from Arrowhead Pharmaceuticals
- REDEMPLO’s launch growth and SHTG preparations led a year of major pipeline advances.ARWR
Q4 2026 - ARO-MAPT cut CSF tau by up to 73% at Day 105, supporting quarterly-or-less-frequent dosing.ARWR
Study update - Breakthrough dual gene knockdown, robust triglyceride therapy, and pipeline innovation drive growth.ARWR
Morgan Stanley 24th Annual Global Healthcare Conference - Pivotal RNAi trial results and new launches set the stage for major growth across multiple indications.ARWR
H.C. Wainwright 28th Annual Global Investment Conference - Strong efficacy, safety, and launch readiness position plozasiran for high-impact SHTG entry.ARWR
12th Annual Cantor Fitzgerald Global Healthcare Conference - Plozasiran delivers robust, sustained efficacy and safety for high-risk SHTG patients.ARWR
KOL event - SHASTA-3/4 trials drove strong efficacy, revenue growth, and global REDEMPLO expansion.ARWR
Q3 2026 - Plozasiran nears launch after robust phase III data, with lung program readouts expected soon.ARWR
Chardan's 8th Annual Genetic Medicines Conference - Q2 FY2025 saw $542.7M revenue, $370.4M net income, and funding secured into 2028.ARWR
Q2 2025